FINANCING AUTHORITY Sample Clauses

FINANCING AUTHORITY. Developer acknowledges and consents to the following: (i) the Agency continuing its practice to issue tax allocation debt through the Authority, a joint powers authority, to avoid having to issue bonds separately for each of its project areas; and (ii) if necessary or convenient, forming a separate joint powers authority to incur any of the Public Financing contemplated in this Financing Plan, with the Approval of Developer.
Sample 1Sample 2
AutoNDA by SimpleDocs
FINANCING AUTHORITY the Xxxxxx County Industrial Facilities and Pollution Control Financing Authority. GAAP: with respect to Granutec, generally accepted accounting principles as in effect in the United States and with respect to Novopharm and Xxxxxxx, generally accepted accounting principles as in effect in Canada.
Sample 1
FINANCING AUTHORITY. A. Establishment. Recognizing the interstate nature of the CWIP and the capabilities of the SRBC as an interstate agency that works throughout the Susquehanna River Basin, the Parties agree that the SRBC will serve as the financing authority for initial implementation of the CWIP, as approved by the Signatory CWIP Partners. The SRBC’s role as the financing authority will sunset on December 31, 2025, with the option for renewal. Whether or not the option for renewal is exercised, funded ongoing or approved projects shall continue until completion or funds are exhausted, whichever occurs first.
Sample 1
FINANCING AUTHORITY. Attest: By: Xxx Xxxxx, Executive Director Xxxxx Xxxxxxxxxxx, Secretary EXHIBIT A DESCRIPTION OF LEASED PROPERTY THE LAND REFERRED TO HEREIN BELOW IS SITUATED IN THE CITY OF SOUTH LAKE TAHOE, COUNTY OF EL DORADO, STATE OF CALIFORNIA AND IS DESCRIBED AS FOLLOWS, TOGETHER WITH IMPROVEMENTS THEREON: PARCEL 1 - 0000 Xxx Xxx Xxxxxxxxx - Fire Station #1: (APN: 027-323-17-100) Lot 41, as shown on the Official Map of Keller Park Subdivision, filed in the Office of the County Recorder of said County on July 19, 1951 in Map Book A, Map No. 202. Excepting therefrom the following: Beginning at the most Northerly corner of Lot 41 as shown and so delineated on that certain Map of Keller Park Subdivision, recorded in Map Book “A” at Page 102, Official Records of El Dorado County, California; thence from said point of beginning South 29°45’ East along the Northeasterly line of said Lot 41, 125.03 feet; thence leaving said line South 60°15’ West, 336.18 feet to a point on the Southwesterly line of said Lot 41; thence North 40°49’ West along said line 127.40 feet to the most Westerly corner of said Lot 41; thence North 60°15’ East along the Northwesterly line of said Lot 41; 360.63 feet to the point of beginning. Also excepting therefrom that portion conveyed to Xxxxxxxx X. Xxxxxx, in the instrument recorded October 6, 1972 in Book 1151 of Official Records, Page 262. Also excepting therefrom that portion conveyed to the City of South Lake Tahoe, in the instrument Recorded March 20, 1974 in Book 1252 of Official Records, Page 185. PARCEL 2 - 0000 Xxxxxxx Xxxxxxxxx - Police Station: (APN: 025-010-21-100) All that portion of Section 3, Township 12 North, Range 18 East, M.D.M., more particularly described as follows: Beginning at the corner common to Lots 1, 2 and 14 of said Section 3; thence along the lot line common to Lot 2 and Lot 14 South 89°26’11” West, 695.04 feet to a point of cap at a non-tangent curve from which the center bears South 30°11’22” West, 640.00 feet; thence Southeasterly along said curve through a central angle of 25°42’14” an arc distance 287.12 feet; thence tangent to said curve South 34°06’24” East, 108.00 feet; thence North 89°26’11” East, 617.42 feet; thence North 18°37’15” East, 303.22 feet to a point on the lot line common to Lot 1 and Lot 14; thence South 89°26’11” West, 287.86 feet to the point of beginning. PARCEL 3 - 1201 Al Tahoe - Bijou Park (APNs: 000-000-000, 000-000-000) [legal description to come] PARCEL 4 - 1176 Xxxxx Xxxxx - Xxxxxxx Xxxx...
Sample 1
FINANCING AUTHORITY. Applicants propose to engage in the transactions described below from time to time, as applicable, through June 30, 2005.
Sample 1
FINANCING AUTHORITY. The estimated costs of the Project, including construction, engineering fees, acquisition of right-of-way and easements, contingencies and administrative expenses, are $709,960, with a portion of such costs anticipated to be paid by available grant moneys from the Kansas Department of Transportation. All or a portion of the costs of the Project, interest on interim financing and associated financing costs shall be payable from the proceeds of general obligation bonds of the City issued under authority of the Act (the “Bonds”).
Sample 1
FINANCING AUTHORITY. [ATTEST] By: ---------------------------- ------------------------------------- Secretary, Board of Commissioners Chairman, Board of Commissioners HARRXX XXXST AND SAVINGS BANK, AS TRUSTEE By: /s/ -------------------------- TRUST OFFICER [INDENTURE OF TRUST DATED AS OF NOVEMBER 1, 1995]
Sample 1
AutoNDA by SimpleDocs

Related to FINANCING AUTHORITY

  • Contracting authority If you are an individual accepting these terms on behalf of an entity, you represent that you have the legal authority to enter into this agreement on that entity’s behalf.

  • Decision-Making Authority BMS shall have the sole decision-making authority for the operations and Commercialization strategies and decisions, including funding and resourcing, related to the Commercialization of Products; provided that such decisions are not inconsistent with the express terms and conditions of this Agreement, including BMS’ diligence obligations set forth in Section 5.1.

  • Signing Authority Will the above-named Partner be able to sign contracts on behalf of the Partnership? ☐ Yes ☐ No Partner 3: with a mailing address of . a.) Ownership: %

  • Regulatory Authority If any regulatory authority having jurisdiction (or any successor boards or agencies), a court of competent jurisdiction or other Governmental Authority with the appropriate jurisdiction (collectively, the ''Regulatory Body'') issues a rule, regulation, law or order that has the effect of cancelling, changing or superseding any term or provision of this Agreement (the ''Regulatory Requirement''), then this Agreement will be deemed modified to the extent necessary to comply with the Regulatory Requirement. Notwithstanding the foregoing, if a Regulatory Body materially modifies the terms and conditions of this Agreement and such modification(s) materially affect the benefits flowing to one or both of the Parties, as determined by either of the Parties within twenty (20) business days of the receipt of the Agreement as materially modified, the Parties agree to attempt in good faith to negotiate an amendment or amendments to this Agreement or take other appropriate action(s) so as to put each Party in effectively the same position in which the Parties would have been had such modification not been made. In the event that, within sixty (60) days or some other time period mutually agreed upon by the Parties after such modification has been made, the Parties are unable to reach agreement as to what, if any, amendments are necessary and fail to take other appropriate action to put each Party in effectively the same position in which the Parties would have been had such modification not been made, then either Party shall have the right to unilaterally terminate this Agreement forthwith.

  • Appointing Authority If the grievance is not settled under Step 1, it may be formally submitted to the appointing authority. The grievance shall be submitted within seven (7) days after receipt of the written decision from Step 2 or the verbal decision of Step 1, whichever applies. Within seven (7) days after receipt of the written grievance, the appointing authority or designated representative shall meet with the employee. Within seven (7) days thereafter, a written decision shall be delivered to the employee.

  • Regulatory Authorities Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, the Company and its subsidiaries: (i) are in compliance in all material respects with all statutes, rules, regulations, ordinances, orders and decrees applicable to the ownership, testing, in humans or laboratory models, development, manufacture, formulation, packaging, processing, recordkeeping, use, distribution, marketing, labeling, promotion, sale, price reporting, reimbursement, storage, import, export or disposal of any product manufactured or distributed by or for the Company or any of its subsidiaries (“Applicable Laws”), except where the failure to so comply would not, individually or in the aggregate, result in a Material Adverse Effect; (ii) to the knowledge of Company and its subsidiaries, have not, either voluntarily or involuntarily, disclosed to any governmental authority any violations of Applicable Laws, except such as would not, individually or in the aggregate, result in a Material Adverse Effect; (iii) have not received any Food and Drug Administration (“FDA”) Form 483 or any foreign counterpart thereof, warning letter, clinical hold notice or untitled letter from the FDA, any Institutional Review Board (as defined by federal regulation at 21 CFR Section 56.102(g)) or any other governmental authority alleging or asserting noncompliance with any Applicable Laws or any licenses, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), except such as would not, individually or in the aggregate, result in a Material Adverse Effect; (iv) have not received notification of nor have reason to believe that any audits by a governmental authority have resulted in a determination that any of their respective products have been improperly reimbursed, except such audits and determinations as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (v) possess all Authorizations (including, without limitation, exemptions under any Investigational Device Exemption or Investigational New Drug Application, as described at 21 CFR Sections 312 and 812, and approvals of any Institutional Review Board), which are in full force and effect, required for the conduct of their respective businesses (and such Authorizations are valid and in full force and effect) and are not in violation of any term of any such Authorizations, except where the failure to possess such Authorization or the violation of such Authorization would not, individually or in the aggregate, result in a Material Adverse Effect; (vi) have not received written notice of any pending or threatened claim, suit, proceeding, clinical hold, hearing, enforcement, audit, investigation, arbitration, suspension, debarment or exclusion from any governmental authority or Institutional Review Board alleging that any of their respective operations or activities is in violation of any Applicable Laws or Authorizations and the Company has no knowledge or reason to believe that any such governmental authority, Institutional Review Board or other non-governmental authority is considering any such claim, suit, proceeding, clinical hold, hearing, enforcement, audit, investigation, arbitration, suspension, debarment or exclusion except for any such claims, suits, proceedings, clinical holds, hearings, enforcements, audits, investigations, arbitrations, suspensions, debarments or exclusions that would not, individually or in the aggregate, result in a Material Adverse Effect; (vii) have not received written notice that any governmental authority or Institutional Review Board has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and the Company has no knowledge or reason to believe that any such governmental authority is considering such action, except for any such actions that would not, individually or in the aggregate, result in a Material Adverse Effect; (viii) have, or have had on their behalf, filed, declared, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as are required by any Applicable Laws or Authorizations, except where the failure to so file, declare, obtain, maintain or submit would not, individually or in the aggregate, result in a Material Adverse Effect and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (ix) have not, either voluntarily or involuntarily, initiated, conducted or issued, or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, warning, “dear doctor” letter or investigator notice relating to an alleged lack of safety or efficacy of any product or product candidate, any alleged product defect, or violation of any material Applicable Laws or Authorizations and the Company is not aware of any facts that would cause the Company or any of its subsidiaries to initiate any such notice or action and the Company has no knowledge or reason to believe that any governmental authority, Institutional Review Board or other non-governmental authority intends to initiate any such notice or action, except for any such notices or actions that would not, individually or in the aggregate, result in a Material Adverse Effect. Any clinical trials conducted by or on behalf of the Company or any of its subsidiaries that are described in the Registration Statement, the General Disclosure Package or the Prospectus were and, if still pending, are being conducted in compliance in all material respects with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all applicable federal, state, local and foreign laws, rules and regulations, including, but not limited to, the Federal Food, Drug, and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312. Any descriptions of studies, tests and preclinical and clinical trials, including any related results and regulatory status, contained in the Registration Statement, the General Disclosure Package or the Prospectus are, and will be, accurate and complete in all material respects. The Company is not aware of any studies, tests or trials the results of which reasonably call into question in any material respect the clinical trial results described or referred to in the Registration Statement, the General Disclosure Package or the Prospectus. Neither the Company nor any of its subsidiaries has received any written notices or other correspondence from the FDA, an Institutional Review Board or other governmental agency requiring or recommending the termination, suspension or material modification of any clinical trials conducted by, or on behalf of, the Company or any of its subsidiaries or in which the Company or any of its subsidiaries has participated.

  • Other Regulatory Approvals Each party hereto shall cooperate and use its reasonable best efforts to promptly prepare and file all necessary documentation to effect all necessary applications, notices, petitions, filings and other documents, and use all reasonable efforts to obtain (and will cooperate with each other in obtaining) any consent, acquiescence, authorization, order or approval of, or any exemption or nonopposition by, any Governmental Entity required to be obtained or made by Parent or the Company or any of their respective Subsidiaries in connection with the Offer and the Merger or the taking of any other action contemplated by this Agreement.

  • PROPER AUTHORITY Each Party represents and warrants that the person executing this Contract on its behalf has full power and authority to enter into this Contract.

  • Developer Authority Consistent with Good Utility Practice and this Agreement, the Developer may take whatever actions or inactions with regard to the Large Generating Facility or the Developer Attachment Facilities during an Emergency State in order to (i) preserve public health and safety, (ii) preserve the reliability of the Large Generating Facility or the Developer Attachment Facilities, (iii) limit or prevent damage, and (iv) expedite restoration of service. Developer shall use Reasonable Efforts to minimize the effect of such actions or inactions on the New York State Transmission System and the Connecting Transmission Owner’s Attachment Facilities. NYISO and Connecting Transmission Owner shall use Reasonable Efforts to assist Developer in such actions.

  • Regulatory Filing In the event that this Interconnection Construction Service Agreement contains any terms that deviate materially from the form included in Attachment P or from the standard terms and conditions in this Appendix 2, the Transmission Provider shall file the executed Interconnection Construction Service Agreement on behalf of itself and the Interconnected Transmission Owner with FERC as a service schedule under the Tariff. Interconnection Customer may request that any information so provided be subject to the confidentiality provisions of Section 17 of this Appendix

Time is Money Join Law Insider Premium to draft better contracts faster.